Fluicell AB (publ) (STO:FLUI)

Market Cap	46.71M +236.6%
Revenue (ttm)	20.15M +162.4%
Net Income	-2.35M
EPS	-1.71
Shares Out	1.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,801
Open	31.40
Previous Close	33.10
Day's Range	30.50 - 34.00
52-Week Range	7.45 - 67.20
Beta	1.98
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Fluicell AB

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Bio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUI

Financial Performance

In 2025, Fluicell AB's revenue was 15.22 million, an increase of 184.54% compared to the previous year's 5.35 million. Losses were -8.33 million, -46.28% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error